Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Emerging perspectives on multidomain phosphatidylinositol transfer proteins

Raghu P., Basak B., Krishnan H.

Narrative Review, published in Biochim Biophys Acta Mol Cell Biol Lipids (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biochim Biophys Acta Mol Cell Biol Lipids (2021)
Reported sample size
—
Source database
Europe PMC
PMID
34098114
PMCID
PMC7611342
DOI
10.1016/j.bbalip.2021.158984
Citations
16

Abstract (original English)

The phosphatidylinositol transfer protein domain (PITP d ) is an evolutionarily conserved protein that is able to transfer phosphatidylinositol between membranes in vitro and in vivo. However some animal genomes also include genes that encode proteins where the PITP d is found in cis with a number of additional domains and recent large scale genome sequencing efforts indicate that this type of multidomain architecture is widespread in the animal kingdom. In Drosophila photoreceptors, the multidomain phosphatidylinositol transfer protein RDGB is required to regulate phosphoinositide turnover during G-protein activated phospholipase C signalling. Recent studies in flies and mammalian cell culture models have begun to elucidate functions for the non-PITP d of RDGB and its vertebrate orthologs. We review emerging evidence on the genomics, functional and cell biological perspectives of these multi-domain PITP d containing proteins.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansDrosophilaPhosphatidylinositolsPhospholipid Transfer ProteinsDrosophila ProteinsSignal TransductionProtein Domains

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.